Skip to main content
SpringerLink
Log in
Book cover

Adverse Events with Biomedicines pp 149–158Cite as

Certolizumab

  • Chapter
  • First Online:

  • 1220 Accesses

Abstract

Certolizumab-pegol (Cimzia®, UCB) is a recombinant humanized Fab fragment composed of a single light and heavy chain derived from a murine IgG2a antibody, conjugated to polyethylene glycol (PEG2MAL40 K). This Fab, produced in E. Coli and subsequently linked to PEG, is directed to soluble and membrane-bound human TNFα, and inhibits its binding to p55 (TNFR1) and p75 (TNFR2) receptors, but it does not neutralize TNFβ.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Certolizumab-Pegol (Cimzia®) BLA/STN 125160 Resubmission FDA Medical Rev 2008

    Google Scholar 

  2. Cimzia® (certolizumab-pegol) EMEA/H/C/740 Refusal Assessment Report 2008

    Google Scholar 

  3. Cimzia® (certolizumab-pegol) Prescribing Information. UCB, 2012

    Google Scholar 

  4. Connock M, Tubeuf S, Malottki K et al (2009) Certolizumab-Pegol (Cimzia®) for the treatment of rheumatoid arthritis. Evidence Review Group Report commissioned by the NIHR HTA programme on behalf of NICE. Queen’s Printer and controller of HMSO, p 1–112

    Google Scholar 

  5. Cimzia® (certolizumab-pegol) EMEA, EPAR Annex I, 2012

    Google Scholar 

  6. Tracey D, Klareskob L, Sasso EH et al (2008) Tumor necrosis factor antagonist mechanism of action: a comprehensive review. Pharmacol Ther 117:244–279

    Article  PubMed  CAS  Google Scholar 

  7. Furst DE, Wallis R, Broder M et al (2006) Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infections. Semin Arthritis Rheum 36:159–167

    Article  PubMed  CAS  Google Scholar 

  8. Horiuki T, Mitoma H, Harashima S et al (2010) Transmembrane TNFα: structure, function and interaction with anti-TNF agents. Rheumatology 49:1215–1228

    Article  Google Scholar 

  9. Shu Q, Amin MA, Ruth JH et al (2012) Suppression of endothelial cell activity by inhibition of TNFα. Arthritis Res Ther 14:R88 (1-15)

    Google Scholar 

  10. Sandborn WJ, Schreiber S, Feagan BG et al (2011) Certolizumab pegol for active Crohn’s disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol 9:670–678

    Article  PubMed  CAS  Google Scholar 

  11. Weinblatt ME, Fleischmann R, Huizinga TWJ et al (2012) Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Rheumatology 51:2204–2214

    Article  PubMed  CAS  Google Scholar 

  12. Keystone EC, Combe B, Smolen J et al (2012) Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial. Rheumatology 51:1628–1638

    Article  PubMed  CAS  Google Scholar 

  13. Choy E, McKenna F, Vencovsky J et al (2012) Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. Rheumatology 51:1226–1234

    Article  PubMed  CAS  Google Scholar 

  14. Ruiz Garcia V, Jobanputra P, Cabello JB et al (2011) Certolizumab pegol (CDP870) for rheumatoid arthritis in adults (Review). Cochrane database of systematic reviews 2011 doi:10.1002/14651858.CD007649.pub2

  15. Bell GM, Reynolds G, Isaacs JD (2011) Biologic therapies in non-rheumatic diseases: lessons for rheumatologists? Nat Rev Rheumatol 7:507–516

    Article  PubMed  CAS  Google Scholar 

  16. RAPID™ -PsA study showed that certolizumab pegol improved the signs and symptoms of psoriasic arthritis. UCB data file CZP-PRR-013318_052012

    Google Scholar 

  17. Reich K, Ortonne J-P, Gottlieb AB et al (2012) Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab’ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. BJD 167:180–190

    Article  CAS  Google Scholar 

  18. Sfikakis PP (2010) The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. In: Kollias G, Sfikakis PP (eds) TNF pathophysiology. Molecular and cellular mechanisms. Curr Dir Autoimmun 11:180–210

    Google Scholar 

  19. Stallmach A, Hagel S, Bruns T (2010) Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol 24:167–182

    Article  PubMed  CAS  Google Scholar 

  20. Rubbert-Roth A (2012) Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology 51:38–47. doi:10.1093/rheumatology/kes114

    Article  Google Scholar 

  21. Horton SC, Nam JL, Buch MH (2012) Safety of biologics in rheumatoid arthritis. Int J Clin Rheumatol 7:425–451

    Article  CAS  Google Scholar 

  22. Stuart ME, Strite SA (2011) Systematic safety review of five biologic antirheumatic drugs. Delfini group p 1–275. (www.delfini.org)

Download references

Author information

Authors and Affiliations

  1. University of Verona, Verona, Italy

    Giuseppe Tridente

Authors
  1. Giuseppe Tridente
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe Tridente .

1 Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (XLS 76 kb)

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Italia

About this chapter

Cite this chapter

Tridente, G. (2014). Certolizumab. In: Adverse Events with Biomedicines. Springer, Milano. https://doi.org/10.1007/978-88-470-5313-7_14

Download citation

Publish with us

Policies and ethics

Search

Navigation